538 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
SNY Sanofi $43.75 $109.14B N/A
Article Searches
Merck's Recarbrio Gets FDA Priority Review for New Indication http://www.zacks.com/stock/news/748727/mercks-recarbrio-gets-fda-priority-review-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-748727 Feb 04, 2020 - The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.
Lilly's NDA for Selpercatinib Gets FDA's Priority Review http://www.zacks.com/stock/news/740824/lillys-nda-for-selpercatinib-gets-fdas-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-740824 Jan 30, 2020 - Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.
Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data http://www.zacks.com/stock/news/738803/biotech-stock-roundup-epzm-drug-gets-fda-nod-xlrn-hepa-surge-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-738803 Jan 29, 2020 - It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.
Are Investors Undervaluing Sanofi (SNY) Right Now? http://www.zacks.com/stock/news/736938/are-investors-undervaluing-sanofi-sny-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-736938 Jan 28, 2020 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SNY vs. NVO: Which Stock Should Value Investors Buy Now? http://www.zacks.com/stock/news/736878/sny-vs-nvo-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-736878 Jan 28, 2020 - SNY vs. NVO: Which Stock Is the Better Value Option?
Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA http://www.zacks.com/stock/news/736759/regeneron-sanofis-sbla-for-dupixent-accepted-by-the-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-736759 Jan 28, 2020 - The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.
Top Stock Analyst Reports for Merck, Broadcom & Sanofi http://www.zacks.com/research-daily/734833/top-stock-analyst-reports-for-merck-broadcom-sanofi?cid=CS-ZC-FT-research_daily-734833 Jan 27, 2020 - Top Stock Analyst Reports for Merck, Broadcom & Sanofi
Should Value Investors Pick Sanofi (SNY) Stock Right Now? http://www.zacks.com/stock/news/728051/should-value-investors-pick-sanofi-sny-stock-right-now?cid=CS-ZC-FT-analyst_blog|value_stocks-728051 Jan 21, 2020 - Is Sanofi (SNY) a great pick from the value investor's perspective right now? Read on to know more.
Novavax Rises on Fast Track Designation to Influenza Vaccine http://www.zacks.com/stock/news/720743/novavax-rises-on-fast-track-designation-to-influenza-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-720743 Jan 16, 2020 - The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate http://www.zacks.com/stock/news/715508/lilly-to-buy-dermira-for-%2411b-add-phase-iii-eczema-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-715508 Jan 13, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.

Pages: 12345678...54

<<<Page 3>